Liu S, Khemlani L S, Shapiro R A, Johnson M L, Liu K, Geller D A, Watkins S C, Goyert S M, Billiar T R
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.
Infect Immun. 1998 Nov;66(11):5089-98. doi: 10.1128/IAI.66.11.5089-5098.1998.
Studies were undertaken to examine hepatocyte CD14 expression during endotoxemia. Our results show that lipopolysaccharide (LPS) treatment in vivo caused a marked upregulation in CD14 mRNA and protein levels in rat hepatocytes. Detectable increases in mRNA were seen as early as 1.5 h after LPS treatment; these increases peaked at 20-fold by 3 h and returned to baseline levels by 24 h. In situ hybridization localized the CD14 mRNA expression to hepatocytes both in vitro and in vivo. Increases in hepatic CD14 protein levels were detectable by 3 h and peaked at 12 h. Hepatocytes from LPS-treated animals expressed greater amounts of cell-associated CD14 protein, and more of the soluble CD14 was released by hepatocytes from LPS-treated rats in vitro. The increases in hepatocyte CD14 expression during endotoxemia occurred in parallel to increases of CD14 levels in plasma. To provide molecular identification of the hepatocyte CD14, we cloned the rat liver CD14 cDNA. The longest clone consists of a 1,591-bp insert containing a 1,116-bp open reading frame. The deduced amino acid sequence is 372 amino acids long, has 81.8 and 62.8% homology to the amino acid sequences of mouse and human CD14, respectively, and is identical to the rat macrophage CD14. The expressed CD14 protein from this clone was functional, as indicated by NF-kappaB activation in response to LPS and fluorescein isothiocyanate-LPS binding in CHO cells stably transfected with rat CD14. A nuclear run-on assay showed that CD14 transcription rates were significantly increased in hepatocytes from LPS-treated animals, indicating that the upregulation in CD14 mRNA levels observed in rat hepatocytes after LPS treatment is dependent, in part, on increased transcription. In vitro and in vivo experiments indicated that interleukin-1beta and/or tumor necrosis factor alpha participate in the upregulation of CD14 mRNA levels in hepatocytes. Our data indicate that hepatocytes express CD14 and that hepatocyte CD14 mRNA and protein levels increase rapidly during endotoxemia. Our observations also support the idea that soluble CD14 is an acute-phase protein and that hepatocytes could be a source for soluble CD14 production.
开展了多项研究以检测内毒素血症期间肝细胞CD14的表达情况。我们的研究结果表明,体内给予脂多糖(LPS)可导致大鼠肝细胞中CD14 mRNA和蛋白水平显著上调。LPS处理后最早在1.5小时即可检测到mRNA增加;这些增加在3小时时达到峰值,为原来的20倍,到24小时时恢复至基线水平。原位杂交显示,体外和体内实验中CD14 mRNA均定位于肝细胞。肝脏CD14蛋白水平在3小时时可检测到增加,并在12小时时达到峰值。LPS处理动物的肝细胞表达更多的细胞相关CD14蛋白,并且在体外实验中,LPS处理大鼠的肝细胞释放出更多的可溶性CD14。内毒素血症期间肝细胞CD14表达的增加与血浆中CD14水平的增加同时出现。为了从分子水平鉴定肝细胞CD14,我们克隆了大鼠肝脏CD14 cDNA。最长的克隆片段包含一个1591 bp的插入片段,其中有一个1116 bp的开放阅读框。推导的氨基酸序列长372个氨基酸,与小鼠和人CD14的氨基酸序列分别具有81.8%和62.8%的同源性,并且与大鼠巨噬细胞CD14相同。该克隆表达的CD14蛋白具有功能,这可通过稳定转染大鼠CD14的CHO细胞中LPS诱导的NF-κB激活以及异硫氰酸荧光素-LPS结合来证明。核转录分析表明,LPS处理动物的肝细胞中CD14转录率显著增加,这表明LPS处理后大鼠肝细胞中观察到的CD14 mRNA水平上调部分依赖于转录增加。体外和体内实验表明,白细胞介素-1β和/或肿瘤坏死因子α参与肝细胞中CD14 mRNA水平的上调。我们的数据表明,肝细胞表达CD14,并且在内毒素血症期间肝细胞CD14 mRNA和蛋白水平迅速增加。我们的观察结果还支持可溶性CD14是一种急性期蛋白以及肝细胞可能是可溶性CD14产生来源的观点。